Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab : results from a multicentric, multinational, retrospective, cohort study
BACKGROUND: Tralokinumab is a human monoclonal antibody targeting interleukin-13 that is approved for the treatment of moderate-severe atopic dermatitis. Studies analyzing the efficacy and safety of tralokinumab in a real-world setting are scarce.
RESEARCH DESIGN AND METHODS: A European, multicentric, real-world, retrospective cohort study was defined to assess the effectiveness and safeness profile of tralokinumab, investigating the achievement of pre-specified treatment goals; and to detect potential differences in terms of effectiveness and safeness across some selected patient subcohorts.
RESULTS: A total of 194 adult patients were included in this study. A significant improvement in physician-assessed disease severity was detected at each follow-up visit as compared with baseline and similar trend was observed for patient-reported outcomes and quality of life. No meaningful difference in effectiveness was found when considering patient age (<65 versus ≥65 years), neither dissecting patient cohort in dupilumab-naive vs dupilumab-treated subjects. Among tralokinumab-treated patients, 88% achieved at least one currently identified real-world therapeutic goal at week 16.
CONCLUSIONS: This retrospective multicenter study confirmed the effectiveness and safeness of tralokinumab throughout 32 weeks of observation, showing the achievement of therapeutic goals identified in both trial and real-world settings in a large proportion of tralokinumab-treated patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Expert opinion on biological therapy - 23(2023), 12 vom: 20. Juli, Seite 1307-1315 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chiricozzi, A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 29.12.2023 Date Revised 22.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14712598.2023.2292627 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365989991 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365989991 | ||
| 003 | DE-627 | ||
| 005 | 20240123231949.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14712598.2023.2292627 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1268.xml |
| 035 | |a (DE-627)NLM365989991 | ||
| 035 | |a (NLM)38108300 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chiricozzi, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab |b results from a multicentric, multinational, retrospective, cohort study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.12.2023 | ||
| 500 | |a Date Revised 22.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Tralokinumab is a human monoclonal antibody targeting interleukin-13 that is approved for the treatment of moderate-severe atopic dermatitis. Studies analyzing the efficacy and safety of tralokinumab in a real-world setting are scarce | ||
| 520 | |a RESEARCH DESIGN AND METHODS: A European, multicentric, real-world, retrospective cohort study was defined to assess the effectiveness and safeness profile of tralokinumab, investigating the achievement of pre-specified treatment goals; and to detect potential differences in terms of effectiveness and safeness across some selected patient subcohorts | ||
| 520 | |a RESULTS: A total of 194 adult patients were included in this study. A significant improvement in physician-assessed disease severity was detected at each follow-up visit as compared with baseline and similar trend was observed for patient-reported outcomes and quality of life. No meaningful difference in effectiveness was found when considering patient age (<65 versus ≥65 years), neither dissecting patient cohort in dupilumab-naive vs dupilumab-treated subjects. Among tralokinumab-treated patients, 88% achieved at least one currently identified real-world therapeutic goal at week 16 | ||
| 520 | |a CONCLUSIONS: This retrospective multicenter study confirmed the effectiveness and safeness of tralokinumab throughout 32 weeks of observation, showing the achievement of therapeutic goals identified in both trial and real-world settings in a large proportion of tralokinumab-treated patients | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Atopic dermatitis | |
| 650 | 4 | |a IL-13 inhibitor | |
| 650 | 4 | |a Treatment goals | |
| 650 | 4 | |a eczema | |
| 650 | 4 | |a tralokinumab | |
| 650 | 7 | |a tralokinumab |2 NLM | |
| 650 | 7 | |a GK1LYB375A |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 700 | 1 | |a Ferrucci, S M |e verfasserin |4 aut | |
| 700 | 1 | |a Di Nardo, L |e verfasserin |4 aut | |
| 700 | 1 | |a Gori, N |e verfasserin |4 aut | |
| 700 | 1 | |a Balato, A |e verfasserin |4 aut | |
| 700 | 1 | |a Ortoncelli, M |e verfasserin |4 aut | |
| 700 | 1 | |a Maurelli, M |e verfasserin |4 aut | |
| 700 | 1 | |a Galluzzo, M |e verfasserin |4 aut | |
| 700 | 1 | |a Munera Campos, M |e verfasserin |4 aut | |
| 700 | 1 | |a Seremet, T |e verfasserin |4 aut | |
| 700 | 1 | |a Caldarola, G |e verfasserin |4 aut | |
| 700 | 1 | |a De Simone, C |e verfasserin |4 aut | |
| 700 | 1 | |a Ippoliti, E |e verfasserin |4 aut | |
| 700 | 1 | |a Torres, T |e verfasserin |4 aut | |
| 700 | 1 | |a Gkalpakiotis, S |e verfasserin |4 aut | |
| 700 | 1 | |a Conrad, C |e verfasserin |4 aut | |
| 700 | 1 | |a Carrascosa, J M |e verfasserin |4 aut | |
| 700 | 1 | |a Bianchi, L |e verfasserin |4 aut | |
| 700 | 1 | |a Argenziano, G |e verfasserin |4 aut | |
| 700 | 1 | |a Ribero, S |e verfasserin |4 aut | |
| 700 | 1 | |a Girolomoni, G |e verfasserin |4 aut | |
| 700 | 1 | |a Marzano, A V |e verfasserin |4 aut | |
| 700 | 1 | |a Peris, K |e verfasserin |4 aut | |
| 700 | 0 | |a MEDaCoTRA Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on biological therapy |d 2001 |g 23(2023), 12 vom: 20. Juli, Seite 1307-1315 |w (DE-627)NLM116190124 |x 1744-7682 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:12 |g day:20 |g month:07 |g pages:1307-1315 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14712598.2023.2292627 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 12 |b 20 |c 07 |h 1307-1315 | ||